Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neurogene Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
NGNE
Nasdaq
2834
www.neurogene.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neurogene Inc.
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
- Nov 18th, 2024 10:25 pm
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
- Nov 18th, 2024 9:14 pm
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
- Nov 18th, 2024 11:45 am
Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal
- Nov 12th, 2024 9:10 pm
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data
- Nov 12th, 2024 11:58 am
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
- Nov 11th, 2024 9:01 pm
Neurogene Secures $200M for Genetic Therapy Development
- Nov 5th, 2024 12:54 pm
Neurogene Announces Oversubscribed $200 Million Private Placement
- Nov 4th, 2024 12:30 pm
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
- Oct 21st, 2024 11:30 am
Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think
- Aug 17th, 2024 2:01 pm
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
- Aug 9th, 2024 11:30 am
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
- Aug 7th, 2024 11:30 am
Neurogene to Participate in BMO Genetic Medicines Summit
- Jul 2nd, 2024 11:30 am
Neurogene Announces Addition to Russell 3000® Index
- Jul 1st, 2024 11:30 am
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
- Jun 18th, 2024 1:26 pm
Neurogene to Participate in Upcoming Conferences
- Jun 5th, 2024 11:30 am
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
- Jun 3rd, 2024 11:30 am
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
- May 10th, 2024 11:30 am
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
- May 7th, 2024 10:19 am
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
- Apr 22nd, 2024 8:36 pm
Scroll